← All Aurinia Pharmaceuticals INC filings

Aurinia Pharmaceuticals INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
AUPH
Aurinia Pharmaceuticals INC
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.47% Stake in Aurinia Pharmaceuticals
Armistice Capital, LLC and Steven Boyd have jointly filed an amended Schedule 13G, reporting a beneficial ownership of 4.47% in Aurinia Pharmaceuticals Inc. as of December 31, 2024.